Some of the key players such as Eisai Inc., Ever Neuro Pharma GmbH, Geny Research Corp, Novartis, Charsire Biotechnology Corp, Merz Pharmaceuticals GmbH, LLC Merz Pharma, Otsuka Pharmaceutical Co., Ltd, Johnson & Johnson Pharmaceutical Research & Development LLC, and many others are actively working to improve the Vascular Dementia treatment dynamics.
DelveInsight’s “Vascular Dementia Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Vascular Dementia market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Vascular Dementia market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Vascular Dementia: An Overview
Vascular dementia (VaD) is an etiological category of dementia characterized by severe cognitive impairment resulting from ischemic or hemorrhagic stroke or hypoperfusion affecting brain regions important for memory, cognition, and behavior. Vascular dementia is a decline in thinking skills caused by conditions that block or reduce blood flow to various brain regions, depriving them of oxygen and nutrients. Cognition and brain function can be significantly affected by the size, location, and number of vascular changes.
According to the Vascular Impairment of Cognition Classification Consensus Study (VICCCS) guideline, VaD can be classified into four major subtypes: Post-stroke dementia (PSD), defined as dementia manifesting within 6 months after a stroke; Subcortical ischemic vascular dementia (SIVAD); Multi-infarct (cortical) dementia; and mixed dementia.
Vascular Dementia Market Key Facts
-
The United States accounts for the largest market size of Vascular Dementia in comparison to EU-5 (Germany, France, Italy, Spain, and the United Kingdom) and Japan.
-
Among the EU-5 countries, Germany had the highest market size, while Spain had the lowest market size.
-
As per the assessment of DelveInsight, the total prevalent cases of dementia in the 7MM were found to be 21,591,000+ in 2021.
-
The diagnosed prevalent cases of dementia in the 7MM were found to be 11,344,000+ in 2021, which are expected to increase at a CAGR of 3.60% for the study period of 2019-2032.
-
Among 7MM, the United States has the highest number of diagnosed cases of Vascular Dementia, with 1,110,606 cases in 2021, equivalent to 40% of total diagnosed prevalent cases in the 7MM.
-
In 2021, Japan had 791,660 diagnosed cases of Vascular Dementia, ranking second-highest among 7MM. These cases are expected to increase by 2032 at a CAGR of 3.37% during the forecasted period (2022–2032).
-
Upcoming therapies such as BAC have the potential to create a significant positive shift in the Vascular Dementia market size.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Vascular Dementia market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Vascular Dementia market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Vascular Dementia Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Vascular Dementia Epidemiology, Segmented as –
-
Prevalent cases of Dementia in the 7MM (2019–2032)
-
Diagnosed cases of Vascular Dementia in the 7MM (2019–2032)
-
Age-specific cases of Vascular Dementia in the 7MM (2019–2032)
-
Diagnosed cases of Dementia in the 7MM (2019–2032)
Vascular Dementia Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Vascular Dementia market or expected to be launched during the study period. The analysis covers the Vascular Dementia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Vascular Dementia pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Vascular Dementia Market Will Evolve and Grow by 2032 @
https://www.delveinsight.com/sample-request/vascular-dementia-market
Vascular Dementia Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for Vascular Dementia. Merz Pharma is leading the therapeutics market with its Vascular Dementia drug candidates in the most advanced stage of clinical development.
The Leading companies in the Vascular Dementia Therapeutics Market Include:
-
Acadia Pharmaceuticals
-
AriBio
-
Charsire Biotechnology Corp
-
CSPC Ouyi Pharmaceutical
-
Cyclerion therapeutics
-
DiaMedica Therapeutics
-
Guangzhou Magpie Pharmaceuticals
-
Materia Medica Holding
-
Merz Pharma
-
ProNeurogen Therapeutics
-
Resverlogix
-
Shineway Pharmaceutical
-
Suven Life Sciences
And Many Others
Vascular Dementia Emerging and Marketed Therapies Covered in the Report Include:
-
Akatinol Memantine: Merz Pharma
-
Butylphthalide soft capsules: CSPC Ouyi Pharmaceutical
-
SaiLuoTong: Shineway Pharmaceutical
-
PNA1: ProNeurogen Therapeutics
-
BAC: Charsire Biotechnology Corp.
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
https://www.delveinsight.com/sample-request/vascular-dementia-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Vascular Dementia Competitive Intelligence Analysis
4. Vascular Dementia Market Overview at a Glance
5. Vascular Dementia Disease Background and Overview
6. Vascular Dementia Patient Journey
7. Vascular Dementia Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Vascular Dementia Treatment Algorithm, Current Treatment, and Medical Practices
9. Vascular Dementia Unmet Needs
10. Key Endpoints of Vascular Dementia Treatment
11. Vascular Dementia Marketed Products
12. Vascular Dementia Emerging Drugs and Latest Therapeutic Advances
13. Vascular Dementia Seven Major Market Analysis
14. Attribute Analysis
15. Vascular Dementia Market Outlook (In US, EU5, and Japan)
16. Vascular Dementia Access and Reimbursement Overview
17. KOL Views on the Vascular Dementia Market
18. Vascular Dementia Market Drivers
19. Vascular Dementia Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/vascular-dementia-market
Take control of your healthcare portfolio with DelveInsight’s comprehensive consulting services. Get in touch and discover how we can help you manage your healthcare portfolio today @ Healthcare Portfolio Management
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/